Key statistics
As of last trade BIOAGE Labs Inc (Y7G:DUS) traded at 16.60, -17.00% below its 52-week high of 20.00, set on Jan 15, 2026.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 16.70 |
|---|---|
| High | 16.70 |
| Low | 16.60 |
| Bid | 16.20 |
| Offer | 16.80 |
| Previous close | 17.00 |
| Average volume | 494.22 |
|---|---|
| Shares outstanding | 41.75m |
| Free float | 40.68m |
| P/E (TTM) | -- |
| Market cap | 842.88m USD |
| EPS (TTM) | -2.04 USD |
Data delayed at least 15 minutes, as of Feb 11 2026 11:30 GMT.
More ▼
Press releases
- Invitation to presentation of BioArctic's fourth quarter report for October - December 2025 on February 18 at 9.30 a.m. CET
- Invitation to presentation of BioArctic's fourth quarter report for October - December 2025 on February 18 at 9.30 a.m. CET
- Sales of Leqembi® totaled 20.7 billion yen in the fourth quarter 2025
- Sales of Leqembi® totaled 20.7 billion yen in the fourth quarter 2025
- Eisai submits Marketing Authorisation Variation to EMA for intravenous maintenance dosing every four weeks with Leqembi® (lecanemab)
- BLA for subcutaneous formulation of Leqembi® accepted in China
- Leqembi included in China's commercial insurance innovative drug list
- Leqembi included in China's commercial insurance innovative drug list
- New Leqembi-data presented at CTAD 2025 suggests potential to delay disease progression by up to 8.3 years with continued treatment
- New Leqembi-data presented at CTAD 2025 suggests potential to delay disease progression by up to 8.3 years with continued treatment
More ▼
